Waqas Ahmad Abbasi

Mr. Waqas Ahmad Abbasi

orcid
waqas_ahmed27@yahoo.com

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SQSajida Qureshi
Sajida Qureshi
Waqas Ahmad AbbasiWaqas Ahmad Abbasi
Waqas Ahmad Abbasi
MQMuhammad Asif Qureshi
Muhammad Asif Qureshi
HJHira Khan Abdul jalil
Hira Khan Abdul jalil
MQMohammed Saeed Quraishy
Mohammed Saeed Quraishy
Background: Barrett’s esophagus (BE), with metaplastic columnar epithelium in the lower esophagus, predisposes patients to esophageal adenocarcinoma (EAC). Despite extensive research, mechanisms underlying BE progression to EAC remain unclear, and no validated biomarkers are available for clinical use. Progastricsin/Pepsinogen-C (PGC), an aspartic proteinase linked to maintaining normal epithelial morphology, is often absent in advanced gastrointestinal malignancies. This study comprehensively investigates PGC expression across cancers, particularly in esophageal cancer (ESCA), to clarify its role in BE progression to EAC. Methods: We utilized multiple bioinformatic platforms (TIMER, UALCAN, cBioPortal, GEPIA, STRING, Metascape, and GEO database) to assess PGC expression, genomic alterations, and correlations with clinicopathological features, survival, and immune infiltration. Additionally, using the GEO dataset, we compared non-dysplastic Barrett’s esophagus (NDBE) patients with those who progressed to malignancy, identifying differentially expressed genes (DEGs), their interactions, and potential roles in progression. Results: PGC was notably upregulated in various cancers, especially in adjacent normal tissues of ESCA. Genomic amplifications of PGC were linked to improved survival in EAC patients, particularly those with high PGC expression, suggesting a protective role. Moreover, PGC expression positively correlated with favorable immune infiltration, notably B cells and CD8+ T cells. Enrichment analysis of downregulated DEGs revealed significant involvement in key biological processes, specifically in extracellular matrix organization. Among the downregulated DEGs, we identified PGC among the top 10 hub genes, underscoring its role in tissue homeostasis. Conclusions: These findings suggest that PGC could serve as a promising biomarker for predicting the high-risk transformation from BE to EAC, offering new insights into EAC progression and future therapeutic targets.

6 October 2024 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
SQSajida Qureshi
Sajida Qureshi
Waqas Ahmad AbbasiWaqas Ahmad Abbasi
Waqas Ahmad Abbasi
HJHira Khan Abdul jalil
Hira Khan Abdul jalil
SMSaba Mughal
Saba Mughal
MQMohammad Saeed Quraishy
Mohammad Saeed Quraishy
Background: Esophageal cancer (EC) remains a significant health challenge in South Asia, with poor prognosis despite advancements in diagnostics and treatment. Identifying and validating prognostic factors is essential for improving patient outcomes. Methods: A prospective study was conducted with 146 biopsy-confirmed EC patients at the Dr. Ruth K.M. Pfau Civil Hospital, Karachi, Pakistan. Clinical and laboratory data were collected and analyzed using descriptive statistics, receiver operating characteristic (ROC) analysis, and the Chi-square test. Survival outcomes were assessed using Kaplan–Meier curves, log-rank tests, and Cox proportional hazard models for univariate and multivariate regression analyses, with statistical significance set at p ≤ 0.05. Results: Bivariate analysis showed significant associations of the neutrophil lymphocyte ratio (NLR) (p = 0.017), C-reactive protein to albumin ratio (CAR) (p = 0.033), red cell distribution width to platelet ratio (RPR) (p = 0.020), and systemic immune-Inflammation index (SII) (p = 0.009) with patient survival. Univariate analysis identified tumor length >10 cm (p = 0.016), T4 stage (p = 0.015), metastasis (p < 0.001), surgery not performed (p < 0.001), and SII (p = 0.022) as significant factors for survival, with higher SII linked to poorer overall survival (p = 0.020). Interestingly, in the multivariate model, only metastasis (p < 0.001) and surgery not performed (p = 0.011) remained significant. Conclusions: Immuno-inflammatory markers may be less pertinent prognostic factors for EC in the South Asian population.

28 May 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SQSajida Qureshi
Sajida Qureshi
Waqas Ahmad AbbasiWaqas Ahmad Abbasi
Waqas Ahmad Abbasi
HJHira Khan Abdul jalil
Hira Khan Abdul jalil
RARaheel Ahmed
Raheel Ahmed
MIMubashir Iqbal
Mubashir Iqbal
MQMohammed Saeed Quraishy
Mohammed Saeed Quraishy
Multidisciplinary tumor boards (MTBs) are essential for optimizing cancer care through collaborative decision-making. However, the concordance between initial surgeons’ recommendations and MTB outcomes, particularly in resource-limited settings, remains underexplored. This study evaluates the agreement between treatment plans proposed initially by surgeons and those finalized through MTB discussions conducted at the same stage of patient evaluation, with a focus on changes in treatment intent between curative and palliative care. A retrospective analysis of 216 patients discussed at bi-weekly MTB meetings between January 2021 and December 2023 at a tertiary care hospital was conducted. Statistical tests, including kappa statistics and concordance analysis were applied to assess the interrater agreement between surgeon-recommended and MTB-finalized decisions and to evaluate changes in treatment intent. A p-value < 0.05 was considered statistically significant. Strong concordance and significant perfect agreement were observed between curative versus palliative decisions of surgeons and MTBs, (Cohen’s kappa = 0.89, p < 0.001). MTB recommendations were added to the surgeons’ suggested plans in 38.4% (n = 83) of cases and replaced them entirely in 25.0% (n = 54) of cases. Shifts in treatment intent from curative to palliative or vice versa were infrequent (2.31%, n = 5), specifically in esophageal and stomach cancers. MTB decisions achieved a 100% implementation rate. This study underscores the critical role of MTBs in collaborative decision-making and their value as an essential tool for consistent, individualized, and evidence-based cancer care.

7 October 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
Waqas Ahmad AbbasiWaqas Ahmad Abbasi
Waqas Ahmad Abbasi
SQSajida Qureshi
Sajida Qureshi
MQMuhammad Asif Qureshi
Muhammad Asif Qureshi
MQMohammad Saeed Quraishy
Mohammad Saeed Quraishy
Esophageal cancer (EC) remains a major global health challenge due to its aggressive nature and poor prognosis. Genetic alterations play a crucial role in tumor progression; however, a deeper understanding of the genetic landscape of EC is essential for identifying novel and potent therapeutic targets. This study aims to identify key genes and their variants with potential pathogenicity driving EC progression. Whole-exome sequencing (WES) was performed on EC samples to identify missense variants. A comprehensive in-silico analysis was conducted using SIFT, FATHMM, PROVEAN, MutationTaster, and LRT to classify high-risk variants. Gene expression, mutation frequency, and prognostic relevance were analyzed using GEPIA and cBioPortal platforms. Protein stability was assessed with MuPro and I-Mutant to evaluate the impact of the identified variant, while protein-protein interaction (PPI) analysis via STRING and enrichment analysis through Metascape were performed to explore associated biological pathways. A total of 331 novel high-risk missense variants were identified across 274 genes and systematically refined, narrowing down to 23 prognostically significant variants in 11 genes (PSMC1, SCN8A, HNRNPA3, RPL23, COL5A2, TBL1XR1, TCP1, HNRNPD, CALM2, ABCC2, and HNRNPA1), which were also among the most differentially expressed in EC. Variants in these genes were predicted to destabilize their corresponding proteins, contributing to EC progression. In-silico survival analysis further indicated significantly worse outcomes for patients harboring alterations in these genes, including others. Protein stability analysis confirmed their destabilizing effects, while functional enrichment highlighted their involvement in key pathways driving tumorigenesis. This study identified 11 key DEGs harboring potentially pathogenic novel missense variants, highlighting vulnerabilities for precision-targeted therapies in EC.